EvolveImmune Therapeutics announced it has nominated a development candidate for a next-generation cancer biotherapeutic targeting solid tumors, triggering an $18 million milestone payment from partner AbbVie. This progress is part of their collaboration to develop multi-specific T cell engagers using EvolveImmune's EVOLVE platform, designed to enhance T-cell tumor-killing ability. The milestone validates the platform's potential to create differentiated cancer therapies and supports ongoing work on additional targets with AbbVie. The collaboration began in October 2024 and aims to address challenges in solid and hematologic tumors through innovative immuno-oncology approaches.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
